OxSonics

Juniper Pharma Services has entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics' proprietary sono-sensitive particles.

OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran, its breakthrough ultrasound-based drug delivery platform,reports that the first patient had been dosed in the treatment cohorts of its first-in-huma

Data presented at the European Symposium on Ultrasound Contrast Imaging also demonstrated consistent SonoTran Particle activation Recruitment underway for Delivery and Efficacy cohorts of Phase 1/2a proof of concept study Oxford, UK - 23 January 2023 - Ox

Oxford, UK - 2nd January 2023 - OxSonics CEO, Jérôme Marzinski, was interviewed by The Medicine Maker as part of their DISCOVERY & DEVELOPMENT series. Please find the print version of the interview here: https://themedicinemaker.com/discovery-development/

Seasoned medtech leader with a proven track record in scaling companies Oxford, UK - 7 November 2022 - OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran, its ultrasound-based drug delivery platform,

Data from collaboration with ADC Therapeutics presented at the EORTC-NCI-AACR Symposium showed SonoTran increased potency of ADCT-601 by 3.3 times Oxford, UK - 31 October 2022 - OxSonics Therapeutics, a clinical-stage company focused on transforming cance

Data presented at the International Oncolytic Virus Conference (IOVC) from a collaboration with Turnstone Biologics. Oxford, UK - 25 October 2022 - OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran,

OxSonics Therapeutics("OxSonics" or the "Company") OxSonics to present encouraging preclinical efficacy data from its collaboration with ADC Therapeutics at the EORTC-NCI-AACR Symposium SonoTran provides increased efficacy of an antibody-drug conjugate (A

Underpins Company's strategy to expand its pipeline of clinical combination studies Oxford, UK - 6th June 2022 - OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, is pleased to